about
The Role of α1-Adrenoceptor Antagonists in the Treatment of Prostate and Other CancersFROGG high-risk prostate cancer workshop: patterns of practice and literature review. Part II post-radical prostatectomyUse of 'sham' radiotherapy in randomized clinical trials.Validation of International Society of Urological Pathology (ISUP) grading for prostatic adenocarcinoma in thin core biopsies using TROG 03.04 'RADAR' trial clinical data.Measuring personal and functional changes in prostate cancer survivors: development and validation of the FADE: data from the TROG 03.04 RADAR trial.Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial.Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.Retrospective evaluation of dosimetric quality for prostate carcinomas treated with 3D conformal, intensity modulated and volumetric modulated arc radiotherapyPhyllodes tumor of the breast.Adverse effects of a multicentre system for ethics approval on the progress of a prospective multicentre trial of cancer treatment: how many patients die waiting?Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study).Accrual to Trans-Tasman Radiation Oncology Group-sponsored trials 2010-2012.FROGG high-risk prostate cancer workshop: patterns of practice and literature review: part I: intact prostate.Primary and secondary bone lymphomas.Why do patients regret their prostate cancer treatment? A systematic review of regret after treatment for localized prostate cancer.Acute and Late Bowel Toxicity in Radiotherapy Patients with Inflammatory Bowel Disease: A Systematic Review.Which patients benefit from post-implant CT dosimetry after real-time intraoperative planning for low dose rate prostate brachytherapy? Case series and systematic literature review.Does psychological resilience buffer against the link between the 5-HTTLPR polymorphism and depression following stress.Psychological resilience aspects that mediate the depressive effects of urinary incontinence in prostate cancer survivors 10 years after treatment with radiation and hormone ablation.Using cluster analysis of anxiety-depression to identify subgroups of prostate cancer patients for targeted treatment planning.Total depression and subtypes in prostate cancer survivors 10 years after treatment.Does resilience 'buffer' against depression in prostate cancer patients? A multi-site replication study.Limitations in the inverse association between psychological resilience and depression in prostate cancer patients experiencing chronic physiological stress.Are single fractions of radiotherapy suitable for plantar fasciitis?Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial.Limited chemotherapy and shrinking field radiotherapy for Osteolymphoma (primary bone lymphoma): results from the trans-Tasman Radiation Oncology Group 99.04 and Australasian Leukaemia and Lymphoma Group LY02 prospective trial.Quality assurance audit: a prospective non-randomised trial of chemotherapy and radiotherapy for osteolymphoma (TROG 99.04/ALLG LY02).The myths about radiotherapy and metastatic Basal cell carcinoma.Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 facUnderstanding the functionality of depression among Australian breast cancer patients: implications for cognitive and behavioural interventions.'Why I feel bad': refinement of the Effects of Prostate Cancer Upon Lifestyle Questionnaire and an initial exploration of its links with anxiety and depression among prostate cancer patients.Differences in major depressive disorder and generalised anxiety disorder symptomatology between prostate cancer patients receiving hormone therapy and those who are not.Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.Factor Structure of the Gotland Scale of Male Depression in Two Samples of Men With Prostate Cancer: Implications for Treating Male Depression.Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group.Associations between reduced telomere length, depressed mood, anhedonia, and irritability in prostate cancer patients: Further evidence for the presence of "male depression"?The Hot Flush Beliefs and Behaviour Scale for Men (HFBBS-Men) undergoing treatment for prostate cancer.Do hormone treatments for prostate cancer cause anxiety and depression?The use of salivary cortisol as an index of chronic stress that correlates with depression in prostate cancer patients.Smoking habits of radiotherapy patients: did the diagnosis of cancer make an impact and is there an opportunity to intervene?
P50
Q26740401-4CCAB956-9028-4190-AB0E-834B33C2E629Q26827690-20FFFB05-7149-4CCD-81F3-F417F56D702EQ30369389-4FB2F2DD-C764-4EF3-9F83-5F8CAAA265F9Q30990917-2228B046-AD98-4F5D-9743-6FDDC99D75C6Q31103934-7107F19A-B872-4FB3-8D80-F0EE7ECA6AEAQ33379488-9BF8EFD3-3D2A-48B0-B0B7-FD4E687FCA01Q33856724-70FB51CC-04AD-4EA1-82C8-88F1AF044ECAQ34247444-8D7A35B5-1271-4DC0-BB8F-3A713517D82AQ34583689-9C9D644E-55D4-4A4E-A130-039D456B170CQ36951277-39E28AD9-6C8F-4CA1-A54C-28BCF0B580F0Q37644528-0D2873C8-EEE8-48E0-935B-08FAD4CAEFC1Q38122788-3A9A4E78-DF70-4A20-8510-AD7FBB8E192BQ38168635-010FFA9E-546D-4873-813A-F9974DECF228Q38362482-42593BD9-8B93-4039-A08B-68387C9F23B6Q38366517-C162C560-0E15-411E-AA3D-58C8CA700CA6Q38506213-6FE8C496-4224-40EE-9C91-BC903C472D98Q38633570-117E4752-C549-4FAF-88DE-EB31AE7B1F59Q38642584-208AC4F2-1DF7-4C42-9D00-67AF80205247Q38894398-BF59C3FB-D240-4CB0-8D9B-74C7A65C7682Q38979620-7225D621-D0C8-46A6-AD3F-466B50EAA8C5Q39075926-B8B45898-E21C-4E6D-82E1-C6E96DDF8A17Q39261932-860CC34F-E8FB-4148-B976-3B5A7016CF3CQ39309388-8400525A-A767-474F-9400-4C590F462EF4Q39378915-5B46BE02-9083-48A6-B3F3-09DE808731C2Q39487473-95B6ED83-1642-46D6-8B78-04F32629BEEFQ39855873-65BA1162-E4F0-4000-B3BE-84AD247AD3C6Q39970949-A0E07442-4F9F-4FFA-9CCB-8D774C1793F1Q42520999-D0FCBE3F-FD4B-4D05-A5B2-0D993B1C5D73Q42677727-9E0F9AA8-B219-4676-BB41-26C5F3AB313FQ43893199-EFB82B15-2DB2-4205-A1FD-B41C204B4CBBQ43919544-3F8E698F-CFB6-4D16-BB2F-83FE35EA5AB2Q46268580-B9F863C9-B8C9-4E32-8B34-DD3E55222F5BQ46781461-229D62B2-F225-48DD-8703-F7EB4165D02AQ47108523-5FE39AAF-3F8F-48FA-A8B4-51301F06E128Q47747715-BF434E80-F931-4A76-B62A-F47670B8D764Q47782515-A80C1DA4-E9FA-48CD-86C5-C672226C481FQ48012402-F833C47A-828B-4390-945B-613AEEA943ADQ48013968-83E08B7C-29A9-472D-BA6E-BAD6DBC0201CQ48026355-317C8C48-790A-47A3-A043-054FC452B041Q48034966-4C7F154D-BB20-448D-807F-47F2986E9AE6
P50
description
investigador
@es
researcher
@en
name
David Christie
@en
David Christie
@nl
type
label
David Christie
@en
David Christie
@nl
prefLabel
David Christie
@en
David Christie
@nl
P31
P496
0000-0001-5494-8751